Head-to-head evidence
albuterol sulfate (Amphastar) vs Ventolin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol sulfate (Amphastar)
Developed by Amphastar Pharmaceuticals, Inc.
NCT01581177 · Phase 2 · completed
The study randomized 23 participants and used triple blinding with placebo and active albuterol comparators, but its small sample and unreported results limit the strength of the evidence. The primary outcome was change in FEV1 AUC, a physiological surrogate measure, and the registry does not state whether this comparison was successful.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
Ventolin
Developed by GlaxoSmithKline
NCT01076322 · Phase 3 · completed
The study randomized participants to treatment sequences and included Ventolin as the active comparator, but it was open-label and small, with an estimated 17 participants. Its primary endpoint, change in FEV1, is a clinical lung-function measure, but no results are posted to show whether the comparison was favorable for Ventolin or met its prespecified objective.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol sulfate (Amphastar)'s landscape · Ventolin's landscape